Evaluation of organ and tumour perfusion by contrast-enhanced ultrasound after transarterial chemoembolization because hepatocellular carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016987

Enrollment

174

Registered

2019-08-23

Start date

2016-05-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: Patients with hepatocellular carcinoma and transarterial chemoembolisation (TACE)

ultrasound and contrast-enhanced ultrasound one day after TACE

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: HCC under Treatment with TACE; Age over 18 years; informed consent.

Exclusion criteria

Exclusion criteria: Pregnancy, breast feeding; suspicion of allergy to Sonovue®; heart insufficiency NYHA III-IV; acute coronary syndrome or unstable Angina pectoris in the last 7 days; cardiac dysrhythmia; acute heart failure; pulmonary Hypertension (PAP> 90mmHg); cardiac Shunts; high blood pressure; dyspnea.

Design outcomes

Primary

Measure	Time frame
Assessment of the target lesion with CEUS after TACE (real time contrast enhancement of the lesion and the liver)	—

Secondary

Measure	Time frame
Assessment of abdominal side effects after TACE	—

Countries

Germany

Contacts

Public ContactNina Weiler

Universitätsklinikum Frankfurt

nina.weiler@kgu.de069/ 6301 5122

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026